Drug Trial Radar · NCT04572152
A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23
Actual
Start
Dec 7, 2020
Primary completion
May 2, 2023
Study completion Aug 31, 2023
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Oct 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human (FIH), Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 (Anti-CD73) in Combination with AK104 in Subjects with Advanced or Metastatic Solid Tumors.
Conditions
- Advanced or Metastatic Solid Tumors
Interventions
AK119Biological
Subjects will receive AK119 by intravenous administration.
AK104Biological
On the same day subjects will receive AK104 by intravenous administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)Time frame: From the time of informed consent signed through 90 days after the last dose of study drug
- Number of participants with a Dose Limiting Toxicity (DLT)Time frame: During the first 6 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Blacktown Cancer and Haematology Centre (Blacktown Hospital)
Blacktown, New South Wales, Australia
ICON Cancer Centre
South Brisbane, Queensland, Australia
Ashford Cancer Centre
Adelaide, South Australia, Australia
Monash Health
Clayton, Victoria, Australia
Alfred Health (The Alfred Hospital)
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.